Novo Nordisk's Market Value Hits $500B with Surging Demand for Wegovy
TL;DR Summary
Novo Nordisk reports its highest annual profit in decades, driven by strong sales of diabetes and obesity drugs like Ozempic and Wegovy. The company is increasing supplies of Wegovy in the US to address shortages, with plans to gradually ramp up supply through 2024. Demand for their GLP-1 drugs has been high, leading to an FDA shortage designation and the emergence of specialized pharmacies making copies of the drug. Novo's annual profit in 2023 reached 83.7 billion Danish kroner, marking its largest annual net profit since 1989, with Ozempic accounting for 41% of total sales and Wegovy bringing in about $4.5 billion in sales.
Topics:business#diabetes-drugs#fda-shortage#healthcare-pharmaceuticals#novo-nordisk#obesity-drugs#wegovy
- Novo Nordisk profit surges as it boosts supplies of Wegovy The Washington Post
- Novo Nordisk says Wegovy is more available after supply boost NBC News
- Ozempic and Wegovy maker Novo Nordisk now worth $500B amid soaring popularity New York Post
- Novo Nordisk Begins Gradually Increasing Supply of Blockbuster Weight-Loss Drug Wegovy The Wall Street Journal
- Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic CNBC
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
74%
395 → 104 words
Want the full story? Read the original article
Read on The Washington Post